Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn
Mankind Pharma Ltd 路 Press Release 路 16 Oct 2026, 1:01 am
Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn Mankind Pharma approved acquiring a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for EUR 48Mn in cash instalments via its wholly owned subsidiary, Mankind Pharma (Netherlands) B.V. To fund this, Mankind raised its investment limit in the Netherlands arm by EUR 45Mn to EUR 50Mn on 15th Oct'26. ACTx develops next-generation CAR-T cancer therapies, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The transaction marks Mankind's strategic entry into global, innovation-led oncology cell therapies.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA 路 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference 路 06 Nov 2026
- Please find attached intimation regarding ESG Rating 路 05 Nov 2026
- Intimation of participation in the Investor Conference. 路 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 路 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL 路 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet 路 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 路 27 Oct 2026
